Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Opthea ( (AU:OPT) ).
The Australian Securities Exchange has released an update on long-term suspended entities, listing companies whose securities have been halted from trading for more than three months and detailing their outstanding financial reporting obligations. The notice outlines specific deadlines by which these entities must lodge overdue accounts and execute plans to have trading in their securities resume, warning that failure to meet the one- and two-year milestones will result in removal from the official list, a move that heightens delisting risk and uncertainty for shareholders in the affected companies.
More about Opthea
Opthea is a biopharmaceutical company focused on developing therapies for eye diseases, particularly retinal conditions that can lead to vision loss. The company targets large global ophthalmology markets where there is ongoing demand for more effective treatments and combination regimens to improve patient outcomes and address unmet medical needs.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$738.8M
For detailed information about OPT stock, go to TipRanks’ Stock Analysis page.